Liquidia Corporation remains a Buy for risk-tolerant biotech investors, supported by strong Yutrepia launch metrics and ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On ...
The following information was released by the National Sleep Foundation:. Brian Clark is a writer and educator based in Los Angeles. His articles have appeared in The Austin Chronicle, Movieline and ...
Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...
Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced that the first patient has been ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...
MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...
Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin ...
Abstract: Electroconvulsive Therapy (ECT) is an effective treatment for treatment-resistant depression and other neurological illnesses. Nevertheless, the precise mechanism by which the dosage and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback